Zdrowie i gospodarka · 06/12/2010
FDA Finalizes Reclassification of Delmont Laboratories' Biological Products
The FDA is issuing a final order reclassifying Delmont Laboratories' Polyvalent Bacterial Antigens with Staphage Lysate into Category II, effectively revoking its license, following a proposal published in 2000. The decision denies Delmont's request for a hearing on the matter.
Source: Federal Register — Health and Human ServicesOpen original release →